{"id":10317,"date":"2022-02-02T12:59:35","date_gmt":"2022-02-02T11:59:35","guid":{"rendered":"https:\/\/ggba.swiss\/merck-rachete-la-societe-biopharmaceutique-genevoise-chord-therapeutics\/"},"modified":"2023-07-04T13:43:48","modified_gmt":"2023-07-04T11:43:48","slug":"merck-rachete-la-societe-biopharmaceutique-genevoise-chord-therapeutics","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/fr\/merck-rachete-la-societe-biopharmaceutique-genevoise-chord-therapeutics\/","title":{"rendered":"Merck rach\u00e8te la soci\u00e9t\u00e9 biopharmaceutique genevoise Chord Therapeutics"},"content":{"rendered":"\n

Chord Therapeutics<\/a> a \u00e9t\u00e9 fond\u00e9e en 2014 et a d\u00e9marr\u00e9 son activit\u00e9 en octobre 2020 suite \u00e0 un financement de s\u00e9rie A par son unique investisseur, Omega Funds<\/a>, une soci\u00e9t\u00e9 internationale de capital-risque de premier plan ax\u00e9e sur la fourniture de m\u00e9dicaments \u00e0 fort impact aux patients.<\/p>\n

Cette soci\u00e9t\u00e9 pharmaceutique genevoise sp\u00e9cialis\u00e9e dans les essais cliniques d\u00e9veloppe des m\u00e9dicaments pour les patients atteints de maladies rares, potentiellement mortelles et gravement invalidantes. Chord fait progresser son principal candidat m\u00e9dicament, le CRD1 (cladribine), la myasth\u00e9nie grave g\u00e9n\u00e9ralis\u00e9e (MGG) ainsi que les troubles du spectre de la neuromy\u00e9lite optique (NMOSD) pour lesquels elle a obtenu la d\u00e9signation de m\u00e9dicament orphelin aux \u00c9tats-Unis.<\/p>\n

La soci\u00e9t\u00e9 biopharmaceutique allemande Merck<\/a> a conclu un accord pour obtenir les droits mondiaux en acqu\u00e9rant Chord Therapeutics, ce qui permettra \u00e0 Merck de d\u00e9velopper la cladribine, le principal candidat-m\u00e9dicament de Chord, pour le traitement de la GMC g\u00e9n\u00e9ralis\u00e9e et de la NMOSD.<\/p>\n

La substance active du CRD1, la cladribine, est approuv\u00e9e aux \u00c9tats-Unis et dans l’Union Europ\u00e9enne pour des traitements oncologiques et pour la scl\u00e9rose en plaques. La s\u00e9curit\u00e9 et la tol\u00e9rance, ainsi que le profil d’efficacit\u00e9 de la cladribine, ont \u00e9t\u00e9 d\u00e9montr\u00e9s chez plusieurs milliers de patients.<\/p>\n

Claudio Nessi, Pr\u00e9sident de Chord Therapeutics et Managing Director chez Omega Funds, a d\u00e9clar\u00e9 : \u00ab\u00a0En tant que seuls investisseurs et fondateurs de Chord, nous avons souscrit tr\u00e8s t\u00f4t \u00e0 la vision d’Arthur Roach selon laquelle le CRD1 (cladribine) devait \u00eatre d\u00e9velopp\u00e9 dans le traitement de la GMC et de la NMOSD. Nous sommes tr\u00e8s heureux que Merck, avec ses ressources et son expertise, poursuive maintenant le travail que nous avons commenc\u00e9, pour apporter ce m\u00e9dicament aux patients qui ont besoin d’une solution s\u00fbre et \u00e9prouv\u00e9e pour traiter leurs maladies.\u00a0\u00bb<\/p>\n

La Suisse occidentale, une r\u00e9gion cl\u00e9 pour Merck<\/h4>\n

Avec l’acquisition r\u00e9cente de Chord Therapeutics et un contrat de plus de EUR 900 millions conclu avec Debiopharm<\/a>, la Suisse occidentale confirme sa position de leader pour la production et le d\u00e9veloppement des m\u00e9dicaments biotechnologiques de Merck.<\/p>\n

Avec des sites de production \u00e0 Corsier-sur-Vevey et \u00e0 Aubonne, ainsi que son futur Biotech Development Center<\/a>, les nombreux investissements de Merck dans la r\u00e9gion au cours des derni\u00e8res ann\u00e9es ont d\u00e9montr\u00e9 l’importance strat\u00e9gique de la Suisse pour le g\u00e9ant pharmaceutique, o\u00f9 l’entreprise emploie plus de 2\u2019500 personnes sur huit sites.<\/p>\n","protected":false},"excerpt":{"rendered":"

Chord Therapeutics, soci\u00e9t\u00e9 biopharmaceutique de phase clinique qui d\u00e9veloppe des m\u00e9dicaments pour des maladies neuroinflammatoires rares, est rachet\u00e9e par Merck.<\/p>\n","protected":false},"author":3,"featured_media":10318,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[843],"tags":[1022,1054,1069],"class_list":["post-10317","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sciences-de-la-vie","tag-biotech-fr","tag-investment-fr","tag-pharma-fr"],"acf":[],"yoast_head":"\nMerck rach\u00e8te la soci\u00e9t\u00e9 biopharmaceutique genevoise Chord Therapeutics - Greater Geneva Bern area<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/fr\/merck-rachete-la-societe-biopharmaceutique-genevoise-chord-therapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck rach\u00e8te la soci\u00e9t\u00e9 biopharmaceutique genevoise Chord Therapeutics - Greater Geneva Bern area\" \/>\n<meta property=\"og:description\" content=\"Chord Therapeutics, soci\u00e9t\u00e9 biopharmaceutique de phase clinique qui d\u00e9veloppe des m\u00e9dicaments pour des maladies neuroinflammatoires rares, est rachet\u00e9e par Merck.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/fr\/merck-rachete-la-societe-biopharmaceutique-genevoise-chord-therapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2022-02-02T11:59:35+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-07-04T11:43:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/staging.ggba.swiss\/app\/uploads\/2023\/06\/Chord-Therapeutics-Merck-630x380-1-2.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"630\" \/>\n\t<meta property=\"og:image:height\" content=\"380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"mathieu\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"mathieu\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/fr\/merck-rachete-la-societe-biopharmaceutique-genevoise-chord-therapeutics\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/merck-rachete-la-societe-biopharmaceutique-genevoise-chord-therapeutics\/\"},\"author\":{\"name\":\"mathieu\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab\"},\"headline\":\"Merck rach\u00e8te la soci\u00e9t\u00e9 biopharmaceutique genevoise Chord Therapeutics\",\"datePublished\":\"2022-02-02T11:59:35+00:00\",\"dateModified\":\"2023-07-04T11:43:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/merck-rachete-la-societe-biopharmaceutique-genevoise-chord-therapeutics\/\"},\"wordCount\":442,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/merck-rachete-la-societe-biopharmaceutique-genevoise-chord-therapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/Chord-Therapeutics-Merck-630x380-1-2.jpeg\",\"keywords\":[\"Biotech\",\"Investment\",\"Pharma\"],\"articleSection\":[\"Sciences de la vie\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/fr\/merck-rachete-la-societe-biopharmaceutique-genevoise-chord-therapeutics\/\",\"url\":\"https:\/\/ggba.swiss\/fr\/merck-rachete-la-societe-biopharmaceutique-genevoise-chord-therapeutics\/\",\"name\":\"Merck rach\u00e8te la soci\u00e9t\u00e9 biopharmaceutique genevoise Chord Therapeutics - Greater Geneva Bern area\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/merck-rachete-la-societe-biopharmaceutique-genevoise-chord-therapeutics\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/merck-rachete-la-societe-biopharmaceutique-genevoise-chord-therapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/Chord-Therapeutics-Merck-630x380-1-2.jpeg\",\"datePublished\":\"2022-02-02T11:59:35+00:00\",\"dateModified\":\"2023-07-04T11:43:48+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab\"},\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/merck-rachete-la-societe-biopharmaceutique-genevoise-chord-therapeutics\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/fr\/merck-rachete-la-societe-biopharmaceutique-genevoise-chord-therapeutics\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ggba.swiss\/fr\/merck-rachete-la-societe-biopharmaceutique-genevoise-chord-therapeutics\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/Chord-Therapeutics-Merck-630x380-1-2.jpeg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/Chord-Therapeutics-Merck-630x380-1-2.jpeg\",\"width\":630,\"height\":380},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/fr\/merck-rachete-la-societe-biopharmaceutique-genevoise-chord-therapeutics\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck rach\u00e8te la soci\u00e9t\u00e9 biopharmaceutique genevoise Chord Therapeutics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab\",\"name\":\"mathieu\",\"url\":\"https:\/\/ggba.swiss\/fr\/author\/mathieu\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck rach\u00e8te la soci\u00e9t\u00e9 biopharmaceutique genevoise Chord Therapeutics - Greater Geneva Bern area","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/fr\/merck-rachete-la-societe-biopharmaceutique-genevoise-chord-therapeutics\/","og_locale":"fr_FR","og_type":"article","og_title":"Merck rach\u00e8te la soci\u00e9t\u00e9 biopharmaceutique genevoise Chord Therapeutics - Greater Geneva Bern area","og_description":"Chord Therapeutics, soci\u00e9t\u00e9 biopharmaceutique de phase clinique qui d\u00e9veloppe des m\u00e9dicaments pour des maladies neuroinflammatoires rares, est rachet\u00e9e par Merck.","og_url":"https:\/\/ggba.swiss\/fr\/merck-rachete-la-societe-biopharmaceutique-genevoise-chord-therapeutics\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2022-02-02T11:59:35+00:00","article_modified_time":"2023-07-04T11:43:48+00:00","og_image":[{"width":630,"height":380,"url":"https:\/\/staging.ggba.swiss\/app\/uploads\/2023\/06\/Chord-Therapeutics-Merck-630x380-1-2.jpeg","type":"image\/jpeg"}],"author":"mathieu","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"mathieu","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/fr\/merck-rachete-la-societe-biopharmaceutique-genevoise-chord-therapeutics\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/fr\/merck-rachete-la-societe-biopharmaceutique-genevoise-chord-therapeutics\/"},"author":{"name":"mathieu","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab"},"headline":"Merck rach\u00e8te la soci\u00e9t\u00e9 biopharmaceutique genevoise Chord Therapeutics","datePublished":"2022-02-02T11:59:35+00:00","dateModified":"2023-07-04T11:43:48+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/merck-rachete-la-societe-biopharmaceutique-genevoise-chord-therapeutics\/"},"wordCount":442,"image":{"@id":"https:\/\/ggba.swiss\/fr\/merck-rachete-la-societe-biopharmaceutique-genevoise-chord-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/Chord-Therapeutics-Merck-630x380-1-2.jpeg","keywords":["Biotech","Investment","Pharma"],"articleSection":["Sciences de la vie"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/fr\/merck-rachete-la-societe-biopharmaceutique-genevoise-chord-therapeutics\/","url":"https:\/\/ggba.swiss\/fr\/merck-rachete-la-societe-biopharmaceutique-genevoise-chord-therapeutics\/","name":"Merck rach\u00e8te la soci\u00e9t\u00e9 biopharmaceutique genevoise Chord Therapeutics - Greater Geneva Bern area","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/merck-rachete-la-societe-biopharmaceutique-genevoise-chord-therapeutics\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/fr\/merck-rachete-la-societe-biopharmaceutique-genevoise-chord-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/Chord-Therapeutics-Merck-630x380-1-2.jpeg","datePublished":"2022-02-02T11:59:35+00:00","dateModified":"2023-07-04T11:43:48+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab"},"breadcrumb":{"@id":"https:\/\/ggba.swiss\/fr\/merck-rachete-la-societe-biopharmaceutique-genevoise-chord-therapeutics\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/fr\/merck-rachete-la-societe-biopharmaceutique-genevoise-chord-therapeutics\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ggba.swiss\/fr\/merck-rachete-la-societe-biopharmaceutique-genevoise-chord-therapeutics\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/Chord-Therapeutics-Merck-630x380-1-2.jpeg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/Chord-Therapeutics-Merck-630x380-1-2.jpeg","width":630,"height":380},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/fr\/merck-rachete-la-societe-biopharmaceutique-genevoise-chord-therapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/fr\/"},{"@type":"ListItem","position":2,"name":"Merck rach\u00e8te la soci\u00e9t\u00e9 biopharmaceutique genevoise Chord Therapeutics"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab","name":"mathieu","url":"https:\/\/ggba.swiss\/fr\/author\/mathieu\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/10317","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/comments?post=10317"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/10317\/revisions"}],"predecessor-version":[{"id":18063,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/10317\/revisions\/18063"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media\/10318"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media?parent=10317"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/categories?post=10317"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/tags?post=10317"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}